Effect of 13-Week Treatment With Vildagliptin as Add-On Therapy to Improve Glucose Variability in Type II Diabetes
A phase 4 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 191 participants.
Also called NCT01862263
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 191 participants
- Sponsor
- Registry
-
NCT01862263
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Mexico
- Registry status
- Terminated
Technical summary
Registry record NCT01862263. Randomized; double masking; primary purpose treatment. Start 2013-05 (registry gives no type); primary completion 2015-07 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Effect of 13-Week Treatment With Vildagliptin as Add-On Therapy to Improve Glucose Variability in Type II Diabetes
- Acronym
- VIDA
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Vildagliptin
- Intervention (Drug)
- Insulin
- Intervention (Drug)
- Placebo
- Lead sponsor
- Novartis Pharmaceuticals
Record details
- Record id
cardio:ct-nct01862263- Content hash
2ff8a9e0f1a3ce20d0b9a5e91b45ad9e2f9d6219447b420f9b682b0be9ca6151